ALC - Dividend announcements

Shareholders approve all agenda items presented R. Scott Herren elected as new independent member of the Board 2025 Compensation Report and Report on Non-Financial Matters approved in consultative votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2026 Annual General Meeting ("AGM"). A total of 283,222,421 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 11,328,896.84, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the

Alcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect R. Scott Herren as a new independent Board member. An accomplished financial executive with thirty-

Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f

Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years of experience in the f

Shareholders approve dividend of CHF 0.24 per share Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election Shareholders approve the 2023 Non-Financial Matters Report in an advisory vote Shareholders approve the Board and Executive Committee compensation in separate binding votes Alcon Inc. (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM). A total of 326,707,870 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of

Alcon welcomes its shareholders to its second in-person AGM In addition to the regular agenda items, shareholders to vote on the Report on Non-Financial Matters Proposed dividend of CHF 0.24 cash per share Alcon (NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024. Alcon is pleased to welcome shareholders to its second in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters. The invitation to t

Shareholders approve dividend of CHF 0.21 per share Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election Shareholders approve all other proposals of the Board of Directors, including the amendment of the Articles of Incorporation, the 2022 Compensation Report in an advisory vote, as well as the Board and Executive Committee compensation in separate binding votes Alcon Inc. (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2023 Annual General Meeting (AGM). A total of 321,168,907 shares with

Alcon welcomes its shareholders to its first in-person AGM In addition to the regular agenda items, Alcon Board of Directors proposes to amend the Articles of Incorporation to conform to recent Swiss corporate law reform Proposed dividend of CHF 0.21 cash per share Alcon (NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 5, 2023. Alcon is pleased to welcome shareholders to its first in-person AGM since becoming an independent, standalone company in April 2019. The company looks forward to hearing directly from its shareholders at this open format meeting. The agenda for this 2023 AGM consists of the regular items as required by law, as we

Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi

Builds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon's core diluted EPS in 2024 Ad hoc announcement pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in

Expands ophthalmic eye drop portfolio leveraging market access expertise and newly created US ophthalmic eye drop sales force EYSUVIS complements Systane Preservative-Free by expanding treatment options for dry eye Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire EYSUVIS® (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals, Inc. The acquisition will complement Alcon's existing portfolio in the large and fast-growing dry eye category. EYSUVIS will complement the Systane® family of eye drops which includes the recently launched Systane Preservative-Fr

Shareholders approve all proposals at the 2022 Annual General Meeting Alcon welcomes Dr. Raquel C. Bono as newly-elected member of the Board Alcon Inc. (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2022 Annual General Meeting (AGM). As a result of the continuing tense situation due to the coronavirus (COVID-19) pandemic, Alcon previously directed shareholders to send their voting instructions to the independent representative, Hartmann Dreyer Attorneys-at-Law. A total of 339,496,103 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,579

Alcon Board of Directors proposes to elect Raquel C. Bono, M.D. as a new Board member Shareholders asked to exercise voting rights exclusively by sending voting instructions to the independent representative due to closed format Proposed dividend of CHF 0.20 cash per share with expected record date of May 2 and payout date on May 5 Alcon (NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 27, 2022. Due to the continuing tense situation due to the COVID-19 pandemic, and as a precautionary and prudent measure, Alcon's Board of Directors decided to hold the AGM in a closed format without the personal attendance of shareholders as permitted by

Alcon will leverage its global footprint and leadership in ophthalmology to drive future growth, bringing this innovative device to more patients worldwide Ivantis associates, including manufacturing and sales, are immediately integrated into Alcon to ensure continuity for new and existing customers Differentiated five-year data demonstrating clinical impact will be showcased at 2022 medical meetings Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the closing of its previously announced acquisition of Ivantis®, developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower e

Expands Alcon's leading surgical portfolio and leverages the company's commercial execution expertise Strong safety and efficacy profile evidenced by five-year study on Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device Indicated to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery*, Hydrus Microstent is part of a large surgical glaucoma market with a growing patient population Ad hoc announcement pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire Ivantis®, developer and manufacturer of the novel Hydrus® Microsten

GENEVA--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will present new data on several of its latest innovations at the British Contact Lens Association (BCLA) 2021 Clinical Conference & Exhibition. Among the 18 Alcon abstracts accepted are data on TOTAL30®, which will be the first and only monthly replacement water gradient contact lens. “We are delighted to partner with the BCLA to present our robust scientific data on several of our products, notably on TOTAL30, which is designed to address two of the key factors to maximise contact lens wearer retention: comfort and vision,” said Cheryl Don

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will present new data on several of its latest innovations at the British Contact Lens Association (BCLA) 2021 Clinical Conference & Exhibition. Among the 18 Alcon abstracts accepted are data on TOTAL30®, which will be the first and only monthly replacement water gradient contact lens. “We are delighted to partner with the BCLA to present our robust scientific data on several of our products, notably on TOTAL30, which is designed to address two of the key factors to maximise contact lens wearer retention: comfort and vision,” said Cheryl Donnelly, Internation

Expands Alcon's existing portfolio and strengthens position in the ophthalmic eye drops market Builds on company's ophthalmic pharmaceutical manufacturing expertise Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza®(brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. The acquisition of Simbrinza combined with the company's existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma market and the fast-growing dry

Alcon Inc. (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the results of its 2021 Annual General Meeting. Given the global COVID-19 outbreak, Alcon previously directed shareholders to send their voting instructions to the independent representative, Hartmann Dreyer Attorneys-at-Law. Shareholders showed a high level of interest and engagement in the resolutions proposed, with a total of 347,227,434 Alcon Inc. shares, corresponding to 70.87% of the shares entitled to vote, represented. Shareholders re-elected Mike Ball as Chair of the Board of Directors and all members of the Board who stood for re-election, namely Lynn Bleil, Arthur

GENEVA--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 28, 2021. As a result of the continuing exceptional circumstances due to the coronavirus (COVID-19) pandemic, the 2021 AGM will be held without the personal attendance of shareholders and shareholders will not be granted access to the meeting room, in accordance with the Ordinance of the Swiss Federal Council regarding measures on combating the coronavirus (COVID-19) as amended on March 1, 2021 (COVID-19 Ordinance 3). Accordingly, and in accordance with the COVID-19 Ordinance 3, shareholders shall exercise their rights at our AGM exclu

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 28, 2021. As a result of the continuing exceptional circumstances due to the coronavirus (COVID-19) pandemic, the 2021 AGM will be held without the personal attendance of shareholders and shareholders will not be granted access to the meeting room, in accordance with the Ordinance of the Swiss Federal Council regarding measures on combating the coronavirus (COVID-19) as amended on March 1, 2021 (COVID-19 Ordinance 3). Accordingly, and in accordance with the COVID-19 Ordinance 3, shareholders shall exercise their rights at our AGM exclusively by sending